AUS
NZ
UK
CA
USA
IND
Healthcare
Neuren Pharmaceuticals Shares Surge 6% on $150 Million PRV Sale
November 06, 2024 03:52 PM AEDT| By Team Kalkine MediaHighlights,Neuren Pharmaceuticals' stock rises 6%, marking its biggest intraday gain since September 27.,The company will receive one-third of the $150 million from the sale of a U.S. FDA pediatric disease priority review voucher (PRV).,Despite the s...
Insider Confidence Rises as Mesoblast Executives Acquire Additional Shares
November 06, 2024 03:28 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast insiders increase holdings, signaling confidence.,Gregory George makes largest purchase, valued at AU$15 million.,Insider ownership of Mesoblast totals around AU$355 million, approximately 24% of the company.,Mesoblast Limited (A...
Tryptamine Therapeutics Advances Clinical Strategy with Board Reshuffle and Strategic Placement
November 06, 2024 02:29 PM AEDT| By Team Kalkine MediaHighlights,Tryptamine Therapeutics acknowledges Peter Molloy's contributions amid board transition.,Strategic placement to support TRP-8803 trial advancements.,New focus on clinical,expertise,with the appointment of Dr. Daniel Tillett.,Tryptamine The...
CardieX Limited (ASX:CDX): Exploring the Journey to Financial Success
November 06, 2024 02:16 PM AEDT| By Team Kalkine MediaHighlights,CardieX Limited is anticipated to achieve profitability by 2026.,Forecasts suggest a strong annual growth rate of 91%.,The company holds a debt level of 79% of its equity.,CardieX Limited (ASX:CDX) is positioned to reach a significant mile...
Freedom Care Group Faces Potential NDIS Ban Amid Program Audit
November 06, 2024 01:29 PM AEDT| By Team Kalkine MediaHighlights,Freedom Care Group faces potential license revocation by NDIS.,Cash flow impact as NDIS program contributes significantly to revenue.,Review triggered following a payment suspension and ongoing audit.,Freedom Care Group (ASX:FCG) recently...
Neuren Pharmaceuticals Gains $50 Million from Priority Review Voucher Sale
November 06, 2024 11:18 AM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals secures $50 million from FDA voucher sale.,The sale is linked to Acadia Pharmaceuticals' Rett syndrome treatment, DAYBUE.,Funds are expected to support,Neuren’s,ongoing neurodevelopmental research.,Neuren Pharmaceuti...
CSL Shares Lag Despite Market Highs, Analysts Remain Optimistic
November 05, 2024 04:57 PM AEDT| By Team Kalkine MediaHighlights,Stock Dip:,CSL shares down nearly 1% in 2024, trading at AU$285.30, off July highs of over AU$312.,Challenges Identified:,Weighed down by the underperformance of Vifor Pharma and regulatory setbacks.,Analyst Optimism:,Brokers maintain a "b...
Biotech Boards That May Face a ‘Second Strike’ Highlighted
November 05, 2024 03:41 PM AEDT| By Team Kalkine MediaHighlights:,A number of biotech companies are facing 'second strike' motions during this AGM season, potentially leading to board spills.,Botanix Pharmaceuticals is advancing its US rollout of Sofdra, despite some shareholder opposition to director p...
Recce Pharmaceuticals Reaches Dosing Milestone in Skin Infection Trial
November 05, 2024 02:58 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals reaches milestone in Phase II trial for R327G gel.,Positive responses,observed,, with no reported Serious Adverse Events.,Trial results,demonstrate,potential in addressing complex skin infections.,Recce Pharmaceutical...
Recce Pharmaceuticals Shows Positive Results in Phase 2 Trial of Topical Gel R327G
November 05, 2024 12:50 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals’ R327G Phase 2 trial meets primary endpoints with promising patient outcomes.,Interim results reveal strong therapeutic responses in patients treated for bacterial skin infections.,The trial reaffirms R327G’s safety a...
PYC Therapeutics Advances Retinitis Pigmentosa 11 Study to Final Stages
November 05, 2024 12:07 PM AEDT| By Team Kalkine MediaHighlights,PYC Therapeutics advances its treatment study for Retinitis Pigmentosa 11.,Higher doses of VP-001 approved for testing in second patient group.,Company aims to,seek,fast-track status from U.S. FDA for this research.,PYC Therapeutics (ASX:P...
Imugene’s (ASX:IMU) VAXINIA Trial Shows Promising Progress in Bile Tract Cancer Treatment
November 05, 2024 11:24 AM AEDT| By Team Kalkine MediaHighlights,Imugene,achieves significant milestone in bile tract cancer treatment.,Patient in VAXINIA Phase 1 trial,maintains,complete response after two years.,U.S. patent extended to 2040, boosting longevity of CF33 oncolytic virotherapy.,Imugene Lt...
NanoViricides (NYSE: NNVC) Showcases Lead Drug Candidate NV-387 at Spartan Capital Investors Conference 2024
November 04, 2024 07:42 PM AEDT| By Team Kalkine MediaHighlights:,NV-387 successfully completes Phase I clinical trials, paving the way for further development.,Demonstrated antiviral activity against Influenza, RSV, COVID, and MPox/Smallpox.,Target market for NV-387 projected to exceed $10 billion by 2...
Positive Outlook Created for Nuclear Medicine Stocks After US Decision
November 04, 2024 03:56 PM AEDT| By Team Kalkine MediaHighlights,Telix Pharmaceuticals secures ongoing favorable US reimbursement for its prostate cancer imaging agent, Illucix.,Optiscan partners with Monash University to develop a flexible, AI-enabled gastrointestinal endomicroscope.,BOD Australia prep...
Impedimed Limited Engages in Share Issuance for Executive Team
November 04, 2024 03:37 PM AEDT| By Team Kalkine MediaHighlights,Impedimed Limited has issued 462,895 fully paid ordinary shares to executives as part of its Executive Share Plan.,This share issuance aligns executive interests with shareholder value, enhancing corporate governance.,The shares will be qu...
Telix Pharmaceuticals (ASX:TLX) Welcomes New US Medicare Payment Rule
November 04, 2024 01:22 PM AEDT| By Team Kalkine MediaHighlights,New US Medicare payment rule boosts,Telix,Pharmaceuticals’ growth outlook.,Rule enables pricing certainty for radiopharmaceutical innovations.,Policy change may promote diagnostic-based decisions over reimbursement structures.,Telix Pharma...
Telix Pharmaceuticals Welcomes CMS Decision on Radiopharmaceutical Payments
November 04, 2024 12:48 PM AEDT| By Team Kalkine MediaHighlights,CMS Decision,: The U.S. Centers for Medicare & Medicaid Services will provide separate payments for specialized diagnostic radiopharmaceuticals starting in 2025, ensuring equitable access for Medicare patients.,Impact on Telix Products,: T...
FDA Grants Argenica Therapeutics Key Designations for Infant Brain Injury Drug
October 30, 2024 06:01 PM AEDT| By Team Kalkine MediaHighlights,Argenica Therapeutics received FDA designations for its infant brain injury drug candidate, ARG-006.,Designations could lead to tax credits, fee exemptions, and potential market exclusivity.,Priority Review Voucher (PRV) possible, enhancin...
Tryptamine Therapeutics (ASX:TYP) Raises A$6M for Psychedelic Trials
October 30, 2024 01:09 PM AEDT| By Team Kalkine MediaHighlights,Tryptamine Therapeutics Ltd,gains,A$6 million funding for clinical trials of TRP-8803.,Major investors include the Merchant Biotech Fund and Dr. Daniel Tillett.,Funds support expanded clinical trials on psilocin’s therapeutic potential.,Tr...
Evaluating the Value and Growth of Pro Medicus Limited (ASX:PME)
October 29, 2024 03:53 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus Limited offers essential radiology IT solutions, supporting global healthcare systems.,The healthcare sector shows resilience and steady growth potential, especially in the IT and data solutions space.,PME’s share price trades...
Advertise your brand on Kalkine Media